Physiologically Based Pharmacokinetic Models of Probenecid and Furosemide to Predict Transporter Mediated Drug-Drug Interactions

被引：0
|
作者：
Hannah Britz
Nina Hanke
Mitchell E. Taub
Ting Wang
Bhagwat Prasad
Éric Fernandez
Peter Stopfer
Valerie Nock
Thorsten Lehr
机构：
[1] Saarland University,Clinical Pharmacy
[2] Drug Metabolism and Pharmacokinetics,Department of Pharmaceutical Sciences
[3] Boehringer Ingelheim Pharmaceuticals Inc.,undefined
[4] Washington State University,undefined
[5] Translational Medicine and Clinical Pharmacology,undefined
[6] Boehringer Ingelheim Pharma GmbH & Co. KG,undefined
来源：
Pharmaceutical Research | 2020年 / 37卷
关键词：
drug-drug interaction (DDI); furosemide; organic anion transporter (OAT); physiologically based pharmacokinetic modeling (PBPK); probenecid;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Physiologically based pharmacokinetic modeling of disposition and drug-drug interactions for atorvastatin and its metabolites
    Zhang, Tao
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2015, 77 : 216 - 229
  • [42] APPLICATION OF PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING IN PREDICTING DRUG-DRUG INTERACTIONS FOR TELMISARTAN IN HUMANS
    Kim, Jeong Ho
    Heo, Hyunjin
    Min, Jee Sun
    Kim, Doyun
    Bae, Soo Hyeon
    Bae, Soo Kyung
    DRUG METABOLISM AND PHARMACOKINETICS, 2017, 32 (01) : S109 - S110
  • [43] PHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) MODELING OF ELAGOLIX FOR PREDICTION OF DRUG-DRUG INTERACTIONS (DDIS)
    Chiney, M. S.
    Polepally, A. R.
    Nader, A. M.
    Dufek, M. B.
    Klein, C. E.
    Ng, J. W.
    Shebley, M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (S1) : S59 - S59
  • [44] Prediction of Pharmacokinetic Drug-Drug Interactions Involving Anlotinib as a Victim by Using Physiologically Based Pharmacokinetic Modeling
    Bu, Fengjiao
    Cho, Yong-Soon
    He, Qingfeng
    Wang, Xiaowen
    Howlader, Saurav
    Kim, Dong-Hyun
    Zhu, Mingshe
    Shin, Jae Gook
    Xiang, Xiaoqiang
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2024, 18 : 4585 - 4600
  • [45] UTILITY AND IMPACT OF PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING TO PREDICT AND INTERPRET DRUG-DRUG INTERACTIONS: CASES OF ASTELLAS PHARMA INC
    Minematsu, Tsuyoshi
    DRUG METABOLISM REVIEWS, 2015, 47 : 6 - 7
  • [46] Developing a physiologically based pharmacokinetic model of apixaban to predict scenarios of drug-drug interactions, renal impairment and paediatric populations
    Xu, Ruijuan
    Tang, Hong
    Chen, Lin
    Ge, Weihong
    Yang, Jin
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 87 (08) : 3244 - 3254
  • [47] Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions with Efavirenz Involving Simultaneous Inducing and Inhibitory Effects on Cytochromes
    Marzolini, Catia
    Rajoli, Rajith
    Battegay, Manuel
    Elzi, Luigia
    Back, David
    Siccardi, Marco
    CLINICAL PHARMACOKINETICS, 2017, 56 (04) : 409 - 420
  • [48] Physiologically-based pharmacokinetic modeling to predict drug-drug interactions of dabigatran etexilate and rivaroxaban in the Chinese older adults
    Sia, Jie En Valerie
    Lai, Xuan
    Wu, Xinyi
    Zhang, Fan
    Li, Haiyan
    Cui, Cheng
    Liu, Dongyang
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2023, 182
  • [49] QUALIFICATION AND APPLICATION OF PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODELING AND SIMULATION (MANDS) TO PREDICT DRUG-DRUG INTERACTIONS FOR ALISERTIB
    Patel, C.
    Ananthula, H.
    Zhou, X.
    Xia, C.
    Chowdhury, S.
    Zhu, A.
    Pusalkar, S.
    Venkatakrishnan, K.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (S1) : S82 - S82
  • [50] Application of physiologically based pharmacokinetic modeling to the prediction of drug-drug and drug-disease interactions for rivaroxaban
    Ruijuan Xu
    Weihong Ge
    Qing Jiang
    European Journal of Clinical Pharmacology, 2018, 74 : 755 - 765
12345